Sensible Medical Innovations

Company Overview

Snapshot

Founded in June 2007 by Amir Ronen, Amir Saroka, Shlomi Bergida, Nadav Mizrahi, and Dan Rappaport, Sensible Medical Innovations operates with 11–50 employees. The company has raised $37.56 million across 5 funding rounds from 4 investors. In September 2025, the company's ReDS Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available to VA medical facilities in the US.

Business overview

Sensible Medical Innovations develops medical radar technology, ReDS, which originated from defense industry applications. This technology is designed for noninvasive monitoring and management of patients with fluid management problems, particularly those living with heart failure, taking diuretic medication, or recovering from coronary artery disease events. The company's products are intended for use by qualified healthcare practitioners and patients in hospitals, hospital-type facilities, and home environments, operating within the Health Tech & Life Sciences sector.

Strategic signal

In September 2025, Sensible Medical's ReDS Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available to VA medical facilities in the US. This development signifies a major milestone for veteran care, indicating strong market validation and expanded access for the company's technology within the critical US healthcare system. For investors, this signals significant growth potential and strategic penetration into a large, government-backed market segment.

Company Intelligence Q&A

What was a key strategic development for Sensible Medical Innovations in September 2025?

In September 2025, Sensible Medical's ReDS Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available to VA medical facilities in the US.

When did Sensible Medical Innovations license its ReDS technology to Bayer?

Sensible Medical Innovations licensed its ReDS technology to Bayer in May 2019.

What significant regulatory clearance did Sensible Medical Innovations receive in August 2015?

In August 2015, Sensible Medical Innovations received FDA 510K clearance for its non-invasive thoracic fluid status monitor.

Which investors participated in Sensible Medical Innovations' funding round in June 2009?

In June 2009, Sensible Medical Innovations received funding from Vitalife and Genesis Partners.

What was the focus of the pilot study mentioned in the company's description?

A pilot study demonstrated that ReDS-guided heart failure management reduced the number of heart failure-related rehospitalizations by approximately 80%.